Ablynx, of Ghent, Belgium, appointed Josefin-Beate Holz chief medical officer.

Advanced Life Sciences Holdings Inc., of Chicago, named Antonio Anzueto, Naga Chalasani, Nathan Dean, Thomas File Jr., Paul Iannini, Donald Low, Lionel Mandell, Mark Metersky, Michael Niederman and Richard Wunderink to its national advisory board for Cethromycin.

AMAG Pharmaceuticals Inc., of Cambridge, Mass., named Lee F. Allen chief medical officer and senior vice president of clinical development.

Avalon Pharmaceuticals Inc., of Germantown, Md., named Bradley G. Lorimier chairman of the board of directors.

BioLineRx Ltd., of Jerusalem, named Tamar Howson, Gil Bianco and Ilan Leviteh to its board of directors.

Hollis-Eden Pharmaceuticals Inc., of San Diego, named Scott M. Freeman, chief medical officer.

Kylin Therapeutics Inc., of West Lafayette, Ind., named Homer L. Pearce to its board of directors.

Metabolex Inc., of Hayward, Calif., appointed Charles A. McWherter senior vice president of research and preclinical development.

Neuromed Pharmaceuticals, of Vancouver, Canada, named Mario Orlando vice president of marketing.

OrthoLogic Corp., of Tempe, Ariz., appointed Michael E. Mendelsohn and Charles A. Dinarello to its scientific advisory board.

Protalix BioTherapeutics Inc., of Carmiel, Israel, named Aaron Ciechanover to its scientific advisory board.

pSivida Ltd., of Perth, Australia, named Katherine Woodthorpe nonexecutive director of the company.

PTC Therapeutics Inc., of South Plainfield, N.J., named Theresa Natalicchio senior vice president of marketing and sales.

Semafore Pharmaceuticals Inc., of Indianapolis, appointed Edward L. Jacobs president and chief executive officer.

Viral Genetics Inc., of Azusa, Calif., appointed Michael Agadjanyan acting director of preclinical development for the Institute for Molecular Medicine.

Xceleron Ltd., of York, England, appointed Joel Schaefer senior director of business development.